Preeclampsia Risk Can't Be Overcome By Taking Antioxidants

According to an Australian study, taking high doses of vitamin C and E supplements during pregnancy in no way helps to cut down the risk of developing preeclampsia in healthy women

According to an Australian study, taking high doses of vitamin C and E supplements during pregnancy in no way helps to cut down the risk of developing preeclampsia in healthy women.

Preeclampsia is a condition in which a pregnant woman experiences after the 20th week of pregnancy elevated blood pressure at a level that could potentially endanger both the woman and the fetus.

According to foodconsumer.org, the study of nearly 2000 women in singleton pregnancies found that those with high intake of vitamin C and E were at the same risk of preeclampsia as those who did not take extra vitamins.

935 women were randomly assigned 1,000 milligrams of vitamin C and 400 international Units of vitamin E daily whereas the remaining 942 women were given a placebo. This regimen was followed from the second trimester of pregnancy to the delivery of the baby.

Researchers found no statistically significant difference between the two groups in terms of their risk of preeclampsia. Around 6 percent of the women in the vitamin group developed preeclampsia compared to 5 percent in the placebo group.

In addition, mortality rates or other serious complications were found in 9.5 percent of cases in the vitamin group compared to 12.1 percent for the placebo group.

The risk of delivering a low birth weight baby was 8.7 percent for women receiving the vitamin therapy compared to 9.9 percent for those receiving a placebo.

Dr. Arun Jeyabalan, an assistant professor in the division of maternal fetal medicine at Magee Women's Hospital at the University of Pittsburgh, said that the trial addressed only low-risk groups and found "vitamin supplementation showed no apparent benefit in reducing the rate of preeclampsia or poor infant outcomes."

Additionally, a larger group of women could provide a definitive answer to this conundrum, Jeyabalan suggested. "This is a treatment that at least for now has no clear benefit and women should not take this therapy without being in a trial situation or without careful consultation with their physician."

"The risk of preeclampsia is definitely less for those women that they included than for those they excluded. It's not surprising that there is no difference in outcome when you look at a low-risk population. If you target really high-risk patients, maybe then you can get an answer," he said.

British researchers had found that increasing the dosage of the vitamins increased the women's risk of having a low birth-weight baby. The study had concluded that high-risk groups of women were better off without the additional vitamin supplementation.

Preeclampsia occurs in approximately 8% of all pregnancies with 15 percent resulting in premature births. Increased risk is associated with first pregnancies, advanced maternal age, African-American heritage, multiple pregnancies, and a past history of diabetes, high blood pressure, or kidney disease.